Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 18

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 18
---
 date of this prospectus, we have issued and sold 11,690 shares of Common Stock for aggregate proceeds of $4,410,616 under the Keystone Equity Financing. We previously filed a registration statement on Form S-1 (File No. 333-278603), which was declared effective by the SEC on May 1, 2024, and remains in effect, with respect to up to: (i) 12,500 Keystone Purchase Shares and (ii) 310 Keystone Commitment Shares. In November 2024, in order to enable us to issue and sell additional shares in excess of the Initial Limit and up to $25,000,000, we entered into the November 2024 Keystone Purchase Agreement with Keystone, pursuant to which we may issue and sell up to $20,589,384 of shares of Common Stock (the “November 2024 Keystone Purchase Shares”). We previously filed a registration statement on S-1 (File No. 333-283492), which was declared effective by the SEC on May 29, 2025, and remains in effect, with respect to up to: (i) 104,318 Keystone Purchase Shares and (ii) 682 Keystone Commitment Shares. As of June 30, 2025, we have issued and sold 100,584 November 2024 Keystone Purchase Shares for aggregate proceeds of $3,098,487 and 3,734 November 2024 Keystone Purchase Shares remain available for issuance under the November 2024 Keystone Purchase Agreement. On July 11, 2025, in order to enable us to issue and sell additional shares, we entered into the New Keystone Purchase Agreement with Keystone, pursuant to which we may issue and sell up to $17,490,897, minus any additional proceeds of sales pursuant to the Prior Registration Statements after June 30, 2025, of shares of Common Stock. We do not have a right to commence any sales of Common Stock to Keystone under the New Keystone Purchase Agreement until the time when all of the conditions to our right to commence sales of Common Stock to Keystone set forth in the New Keystone Purchase Agreement have been satisfied, including the effectiveness of the registration statement of which this prospectus forms a part. We will control the timing and amount of any sales of Common Stock to Keystone. Actual sales of shares of Common Stock to Keystone under the Keystone Purchase Agreements will depend on a variety of factors to be determined by us from time to time, including, among others, market conditions